The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 35)
Research Grant, 2018
Using pre-clinical models of Parkinson' disease (PD), we found CD163-positive macrophages -- immune cells with the CD163 protein on their surface -- to play an active role in neurodegeneration. We also found that in human samples CD163 is modified as a result of PD-related processes in the nervous system. Furthermore, these changes in CD163 correlated with PD symptoms. Together, t...
Researchers: Marina Romero-Ramos, PhD
Therapeutic Pipeline Program, 2018
Many people with Parkinson's disease (PD) have an abnormal glucocerebrosidase (GBA) enzyme, which causes them to accumulate fatty acids -- chemicals that make up fat -- in the brain and other organs. The exact relationship between Parkinson's and GBA abnormalities is unclear. Recent research findings suggest that replacing the abnormal, dysfunctional GBA with its functional form de...
Researchers: Jennyfer Bultinck, PhD
Inflammation Biomarkers Program, 2018
Mutations (changes) in GBA1, the gene that directs the production of the glucocerebrosidase (GBA) protein, can increase the risk of Parkinson's disease (PD) in some people, but not in everyone. Why some people with GBA1 mutations develop Parkinson's and others do not is currently unknown. In our study, we will assess inflammation in people with PD with and without GBA1 mutations t...
Target Advancement Program, 2018
Lysosomes -- tiny bubbles inside the cell responsible for disposing of its waste -- don't work as they should in brain cells of people with Parkinson's disease (PD). Lysosomes are filled with various substances, one of which is ceramide. Ceramide metabolism --production and breakdown -- in lysosomes is controlled by four genes (GBA, GALC, SMPD1 and ASAH1), changes (mutations) in w...
Researchers: Benoît Vanderperre, PhD
Research Grant, 2017
Mutations in the LRRK2 and GBA genes increase the risk for Parkinson's disease (PD). The mechanism by which these mutations increase PD risk is unknown. One potential explanation may be that the activity of the enzymes (chemicals that increase chemical reactions) encoded by these genes is increased (as suspected in LRRK2) or reduced (as suspected in GBA). The purpose of this stud...